<DOC>
	<DOCNO>NCT01685892</DOCNO>
	<brief_summary>This multi-center , open-label , dose-finding study evaluate safety pharmacokinetics venetoclax ( GDC-0199 ; ABT-199 ) administer combination obinutuzumab participant relapsed/refractory previously untreated chronic lymphocytic leukemia . All participant ( relapsed/refractory previously untreated ) receive 6 cycle obinutuzumab venetoclax . After complete combination treatment , previously untreated participant receive single agent venetoclax least 6 additional month ( anticipated time treatment previously untreated participant least 12 month ) . After complete combination treatment , relapsed/refractory participant continue single agent venetoclax disease progression .</brief_summary>
	<brief_title>A Study Venetoclax ( GDC-0199 ; ABT-199 ) Combination With Obinutuzumab Participants With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Diagnosis relapsing/refractory previously untreated chronic lymphocytic leukemia Eastern Cooperative Oncology Group ( ECOG ) performance score &lt; /=1 Adequate bone marrow function Adequate coagulation , renal hepatic function Female patient must surgically sterile , postmenopausal ( least 1 year ) , negative result pregnancy test All female patient surgically sterile postmenopausal ( least 1 year ) nonvasectomized male patient must practice least one method birth control study participation 30 day last dose venetoclax 18 month last dose obinutuzumab , whichever later For woman postmenopausal ( &gt; /= 12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use single combine contraceptive method result failure rate &lt; 1 % per year treatment period least 30 day last dose venetoclax 18 month last dose obinutuzumab , whichever long Men must remain abstinent use condom plus additional contraceptive method together result failure rate &lt; 1 % per year treatment period least 90 day last dose venetoclax 18 month last dose obinutuzumab . Infection human immunodeficiency virus , hepatitis B , hepatitis C Uncontrolled autoimmune hemolytic anemia thrombocytopenia Investigational anticancer therapy within 5 halflives first drug administration History significant renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , cardiovascular , hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>